- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 15 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government how many elective surgeries have been completed at NHS Golden Jubilee's National Treatment Centre since it opened to date, broken down by month.
Answer
The following table provides a breakdown of the core activity undertaken at the National Eye Centre at NHS Golden Jubilee, by month, since it opened in November 2020 up to the end of June 2022.
This does not include activity undertaken in main theatres at the NHS Golden Jubilee University National Hospital in 2020-21 prior to the National Eye Centre opening, nor any activity carried out in the National Eye Centre as part of the current independent sector contracts.
| | | | | | Eye Centre Activity | | | | | | |
| April | May | June | July | August | September | October | November | December | January | February | March | Total |
2020-2021 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 177 | 682 | 693 | 749 | 867 | 3168 |
2021-2022 | 689 | 748 | 704 | 692 | 729 | 768 | 600 | 854 | 783 | 690 | 694 | 770 | 8721 |
2022-2023 | 743 | 894 | 924 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2561 |
Source: NHS Golden Jubilee Management Information
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 22 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government, in light of reports that the Department of Health and Social Care has asked NICE to conduct an appraisal of tixagevimab–cilgavimab, also known as Evusheld, whether it will refer Evusheld to the Scottish Medicines Consortium, in order to ensure that patients in Scotland are able to access this preventative treatment for COVID-19.
Answer
The Scottish Medicines Consortium (SMC) is a partner in a UK-wide multi-agency RAPID C-19 initiative, which is a collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE). Building on this work, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Tuesday, 06 September 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether it will include blood cancer-specific questions as part of the next Scottish Cancer Patient Experience Survey, and if this is the case, whether any data collected will be broken down by cancer type to facilitate comparison between blood cancers and solid tumour cancers.
Answer
The questions used in the next Scottish Cancer Patient Experience Survey will be relevant to all cancer patients including those with blood cancer. The data collected will be broken down by cancer type and published as it has been in previous years.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Tuesday, 06 September 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what discussions it has had with NHS Education for Scotland regarding specific training for primary care staff on identifying symptoms of and diagnosing blood cancer.
Answer
Scottish Government officials are meeting with NHS Education Scotland on 27 September to explore primary care cancer education. This follows the recent cessation of Cancer Research UK’s Clinical Engagement Team that played a key role in delivering cancer education across NHS Scotland in recent years.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether any NHS board is failing to meet national stroke service standards.
Answer
The Scottish Stroke Improvement Programme report, published on 28 June, includes data from the Scottish Stroke Care Audit (SSCA). The SSCA measures quality of care of stroke services in each acute hospital, grouped by NHS board against the Scottish Stroke Care Standards.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether vulnerable people will have access to the drug, Evusheld, to protect against COVID-19 and, if so, when this will become available.
Answer
I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what its response is regarding any impact on Scotland of reports that the UK Government will not procure the COVID-19 drug, Evusheld, to treat vulnerable patients this winter.
Answer
Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.
Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.
The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what action is being taken by any NHS boards that are currently not meeting the national stroke service standard to achieve the necessary standards of service.
Answer
The Scottish Stroke Improvement Programme (SSIP) Lead conducts a review process and meets with all NHS boards to understand the provision of stroke services and create a local action plan to improve performance where needed.
We recognise that the Scottish Stroke Care Standards are challenging for the service and expect Stroke Managed Clinical Networks and Health Boards to work together to drive forward quality improvement programmes of work to achieve these.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government how it plans to restore NHS stroke care, specifically the national stroke care bundle, to its pre-COVID-19 pandemic quality service standard.
Answer
I refer the member to the answer to question S6W-10404 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether all people who were on the former shielding list are eligible for anti-viral medication for the treatment of COVID-19.
Answer
I refer the member to the answer to question S6W-09978 on 24 August 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.